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Linagliptin (LGT) is used to reduce glucose blood levels in patients with type 2 Diabetes mellitus. The proposed conditions for a 
biowaiver guide can be applied due to high solubility of linagliptin in aqueous media. The aim of the present study was to develop 
and validate a dissolution test for 5 mg linagliptin coated tablets. After diverse dissolution procedure evaluation, the selected 
method was achieved using USP apparatus 1 (basket) at 75 rpm and 900 mL of pH 3.5 citrate buffer as dissolution medium. The 
conditions proposed by biowaiver guide were also applied to this drug, using USP apparatus 2 (paddle) and 900 mL of 0.1 M HCl, 
pH 4.5 acetate buffer and pH 6.8 phosphate buffer as dissolution medium. HPLC and UV spectrophotometry were used to LGT 
quantitation and validated for this purpose. The chromatographic and spectrophotometric methods in the dissolution context 
proved to be linear in 0.5 – 20.0 μg.mL-1 range, precise with RSD values less than 1.0% and 2.0%, respectively, and accurate 
(mean recovery 100.29% and 100.59%). The parameters such as specificity, linearity, accuracy, precision and robustness were 
according to international guidelines for both methods HPLC and UV. Dissolved linagliptin results obtained by the two analytical 
methods were compared using the Student’s t-test and the data found were not significant different (p>0.05). In most dissolution 
conditions evaluated, LGT presented more than 85% drug dissolved from the tablets in fifteen minutes. The proposed methods can 
be applied for quality control of this gliptin. According to the results, linagliptin may be a biowaiver candidate.  
 
Keywords: Linagliptin; Dissolution test; UV spectrophotometric method; HPLC method; Biowaiver; Quality control. 
 
Introduction 
 
Diabetes Mellitus (DM) is one of the most common non-
transmissible diseases worldwide1. Linagliptin (LGT), 
approved by FDA in May 2011 is a member of the Gliptins 
class whose act to inhibit the dipeptidyl-peptidase-4 enzyme. 
This class is used to reduce glucose levels in patients with 
type 2 DM, preventing the destruction of the incretins, 
which are hormones that stimulate the pancreas to produce 
insulin when the glucose level in blood is high.2,3 
The dissolution test is considered an important tool to 
characterize a pharmaceutical product. It supplies useful 
information regarding drug release, both in research and 
development and in the production and quality control of 
pharmaceutical forms.4 The dissolution kinetics is associated 
with the absorption of the drug by the organism, interfering 
in the bioavailability and leading to in vitro-in vivo 
correlation (IVIVC) in some cases.5  
Drugs can be classified according to solubility and 
permeability, constituting the Biopharmaceutical 
Classification System (BCS). The FDA has 
recommendations to carry out dissolution tests for oral solid 
pharmaceutical forms of immediate release, and the 
knowledge related to solubility, permeability, dissolution 
and pharmacokinetics must be considered to define 
dissolution specifications, aiming to achieve drug 
registration.6  
LGT is a drug that was suggested as BCS class III by 
Boehringer Ingelheim® itself - the laboratory that launched 
the molecule - as LGT has high solubility and low 
bioavailability.3,7 This approach indicates that dissolution is 
a factor that is most unlikely to limit absorption and the drug 
could be included in the biowaiver program.6,8 For these 
candidate drugs, it is proposed to substitute the studies of 
relative bioavailability/bioequivalence by in vitro 
assays.6,9,10 For BCS class III drug products, if the drug 
substance is highly soluble and the drug product is very 
rapidly dissolving, the biowaiver guidance could be 
applicable. According to the FDA information, LGT is 
mildly soluble in water (0.9 mg.mL-1), soluble in methanol 
(60 mg.mL-1), moderately soluble in ethanol (about 10 
mg.mL-1), mildly soluble in isopropanol (< 1 mg.mL-1) and 
mildly soluble in acetone (about 1 mg.mL-1).3 Wherefore, 
LGT tablet dose of 5 mg requires less than 10 mL of water 
for its solubilization. 
Otherwise, mild dissolution conditions promoting slower 
drug dissolution in the begging of the process usually give 
better application for define tablet composition. 
Therefore, in this work, dissolution studies were conducted 
using commercial tablets to quantifying the drug, both by 
UV/VIS spectrophotometry and by HPLC-DAD, and 
statistical analysis was performed to verify possible 
interchangeability between the two methods proposed. 
Biowaiver approach and dissolution conditions for the 
product developing were focused. 
 
Material and Methods 
 
Material and Reagents 
 
Linagliptin-coated tablets containing 5 mg (Trayenta®), used 
in the dissolution assay, were acquired at local businesses. 
Excipients being in the tablets are mannitol, pregelatinized 
starch, cornstarch, copovidone, and magnesium stearate. In 
addition, the film coating contains the following inactive 
ingredients: hypromellose, titanium dioxide, talc, 
polyethylene glycol, and red ferric oxide. The reference 
standard of LGT was purchased from Sequoia Research 
Products (Oxford, UK) and it was properly characterized for 
this work.11 
Chromatographic analysis was performed by using an 
Eclipse Zorbax C8 column (5 μm; 150 x 4.6 mm - Agilent®), 
PVDF sample filters (13 mm, 0.45 μm - Merck®) and PVDF 
filtration membrane (47 mm, 0.45 μm - Merck®). 
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Instrumentation 
 
All analyses were performed in a Vankel® dissolution 
apparatus (model VK 7010), composed by an automatic 
sampler (VK8000) and equipped with eight glass vessels. 
Quantification by HPLC was conducted by using 
Shimadzu® 20-A equipment with a CBM-20 A system 
controller, LC-20AT pump, SIL-20A/C autosampler, CTO-
20A/C oven and diode array detector SPD-M20A (Kyoto, 
Japan). The LC-Solution software was used to control the 
equipment and to calculate the data and system responses. 
Quantification by spectrophotometry in UV-Vis region was 
performed by using Shimadzu UV-1601PC equipment. 
 
Dissolution test conditions 
 
The dissolution media 0.1 M HCl, pH 3.5 50 mM sodium 
citrate buffer, pH 4.5 50 mM sodium acetate buffer and pH 
6.8 50 mM potassium phosphate buffer were evaluated in 
the dissolution method. Paddle (50 rpm) and basket (75 rpm) 
apparatus were employed. In order to establish the 
dissolution profile, aliquots were collected at times 5, 10, 
15, 20, 30, 45, 60 and 90 minutes, and the volumes removed 
were equivalent to 10 mL, without replacement of the 
medium. The temperature was set in 37 ± 0.5 °C. Filters of 
10 μm were assembled in each vessel cannula. During the 
development phase, drug concentration in the dissolution 
media was determined by ultraviolet spectrophotometry and 
for the dissolution method validation high performance 
liquid chromatography was also used.  
In order to verify whether LGT and these tablets could be 
classified in biowaiver approach, the assays performed in 
the dissolution media 0.1 M HCl, pH 4.5 acetate buffer and 
pH 6.8 phosphate buffer were conducted with n=12 in each 
condition.6 The tests were carried out on the same day and 
the dissolution profiles were obtained by HPLC. The 
quantities of the LGT aliquoted were always included in the 
calculation of the dissolved percentage. Since LGT was in 
the form of coated tablets, the conditions of the dissolution 
test advocated by the guidelines are medium volume of 900 
mL, 50 rpm rotation and apparatus 2 (paddle) with at least 
three different media. The pH values of the dissolution 
media were measured before and after the drug tests. 
 
Dissolution method validation 
 
In dissolution test validation, the following mandatory 
parameters were conducted: specificity, linearity and range, 
repeatability, intermediate precision and accuracy. To 
complement the validation, the degassing need of the 
medium was also evaluated. 
After choosing a dissolution condition from diverse ones 
tested, the accuracy and precision method were validated 
collecting a single aliquot of 10 mL in a 30 minutes time 
period, filtered in a Vankel filter (10 μm), submitted to 
another filtration in a 0.45 μm nylon filter and analyzed by 
HPLC and UV at 293 nm wavelength. Basket (USP 
apparatus I) set in 75 rpm and pH 3.5 sodium citrate buffer 
were used in this validation procedure. 
Assays were performed on two consecutive days and the 
dissolution profiles were obtained by HPLC, with an 
injection volume of 40 μL from each sample, and by UV 
spectrophotometry with triplicate analysis for both. The 
aliquoted medium was not replaced but the quantities of 
LGT removed were included in the calculation of the 
dissolved percentage. 
 
Preparation of the standard solution of LGT 
 
Standard solution was prepared in the selected medium pH 
3.5 citrate buffer, using 10 mg of LGT reference standard. 
The final concentration of stock solution was 1.0 mg.mL-1. 
This solution was diluted in pH 3.5 citrate buffer and filtered 
through a 0.45 µm membrane before injection into the 
chromatographic column. 
 
Preparation and assay of the sample used to evaluate 
precision and accuracy 
 
Twenty LGT tablets were weighed and the mean weight was 
obtained. They were crushed, forming a pool kept in an 
amber glass flask that was used for the validation assays. 
For the crushed powder assay, an equivalent mass to a mean 
weight of the tablets was transferred to a 50 mL volumetric 
flask, solubilized in pH 3.5 citrate buffer, shaken 
mechanically at 200 rpm for 20 minutes and put in an 
ultrasound bath for 15 minutes. After filtration, a ten fold 
dilution was performed to obtain a LGT theoretical 
concentration of 10 μg.mL-1.  
Samples were analyzed by HPLC, on two consecutive days 
performing 12 replications. The content obtained in the 
tablets pool assaying was used to correct the amount of LGT 
used in the precision and accuracy evaluations throughout 
the execution of the dissolution validation procedure. 
 
Specificity 
 
Specificity was executed by analyzing formulation placebo, 
produced from the excipients described in the composition 
of the coated tablet, submitted to the same conditions as the 
LGT tablets in the two quantitative methods tested. 
 
Linearity 
 
Standard curves were prepared from the standard solution of 
LGT at concentrations of 0.5, 2.5, 5.0, 10.0, 15.0 and 20.0 
μg.mL-1, using pH 3.5 citrate buffer as a diluent, evaluated 
in the HPLC and UV quantification techniques. 
 
Accuracy / Precision 
 
After assaying the crushed tablets, three LGT levels for the 
recovery evaluation of the dissolution method were 
established. The levels and the crushed tablets masses that 
contained the indicated drug quantity according to the 
content found at assay are shown in Table 1, in order to add 
strictly the amounts of LGT indicated in the dissolution 
vessels. The medium aliquots were quantified both by 
HPLC and by UV spectrophotometry. 
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Table 1. Levels used to determine the concentration of LGT in the 
accuracy assay 
Level 
% in 
relation to 
the dose 
Quantity of 
drug 
Quantity of 
crushed 
tablets  
Low 80 % 4 mg 147.98 mg 
Medium 100 % 5 mg 184.97 mg 
High 120 % 6 mg 221.96 mg 
 
The assays occurred on two consecutive days using three 
vessels for each level, totalizing six intralevel assays and 18  
interlevel assays. Method precision was evaluated through 
the intralevel relative standard deviation (RSD) at each day 
(n=3) and on different days (n=6). The interlevel precision 
was also computed (n=18). 
 
Degassing need (robustness) 
 
The interference of the presence of bubbles in the medium 
was evaluated. The presence of air bubbles in the system 
may interfere in the results, because acting as a barrier to 
dissolution, make it easier for particles to adhere both on the 
vessel surfaces and on the shaking mechanisms.12 The media 
were degassed using an ultrasound bath for 20 minutes, as 
per previous tests. 
 
Results 
 
According to dissolution guidelines, the three different 
media with the most significant pH values of the 
gastrointestinal tract: 0.1 M HCl solution (pH ~1,2), pH 4.5 
acetate buffer and pH 6.8 phosphate buffer were tested. Fast 
LGT dissolution from the tablets were obtained (> 80% in 
15 minutes) using the paddle apparatus with a rotation 
velocity of 50 rpm. A fourth buffer with a perspective of 
retarding dissolution (pH 3.5 citrate)8 was also employed 
(Figure 1) with this apparatus, since the dosage form is a 
coated tabled of immediate release. 
 
 
Figure 1. LTG dissolution profiles obtained in the media 0.1 M 
HCl, pH 3.5 citrate buffer, pH 4.5 acetate buffer and pH 6.8 
phosphate buffer (n=2) with paddle apparatus (50 rpm) and 900 
mL volume. 
 
Additionally, another pH values were tested employing 
citrate buffer: 5.5 and 6.5 with paddle apparatus at 50 rpm, 
in order to promote slower drug dissolution in the begging 
of the process; that aim usually gives better application for 
define tablet composition. It was observed that as pH 
decreased, the dissolution of LGT presented slower kinetics 
in a 20 minutes period.  
The basket 75 rpm was also used with the same buffers at 
pH 3.5 and 5.5 and with 500 and 900 mL volumes. There 
was small difference in dissolution between the volumes 
tested, 500 and 900 mL, however it was decided to use 900 
mL due to the possibility of taking 10 mL aliquots at the 
times established and to maintain a considerable medium 
volume above the basket (Figure 2).  
Citrate buffer pH 3.5 and basket apparatus at 75 rpm was the 
chosen condition for subsequent dissolution validation steps 
aiming to detect possible differences between lots in the 
quality control routine analysis. 
 
 
Figure 2. Citrate buffer in basket 75 rpm apparatus at pH 3.5 and 
different volumes (*500 mL and **900 mL) (n=2) 
 
Specificity evaluation by UV method, both spectra of 
placebo and sample were traced in the region of 400 to 200 
nm using pH 3.5 citrate buffer medium. Figure 3 shows the 
superposed spectra of LGT sample at the concentration of 
10 μg.mL-1 and the placebo at evaluated range. Absorption 
of the placebo excipients occurred in the range of 200 to 210 
nm, but in the two maximum absorptions of the LGT at 225 
nm and 293 nm there is no interference from these 
excipients. At LGT quantitation by UV spectrophotometry, 
293 nm wavelength was used. In the HPLC method there 
was also no interference in the quantification of the drug in 
employed conditions. Figure 4 shows the superposed 
chromatograms of LGT tablets and excipients solutions in 
293 nm wavelength selected for LGT quantitation. 
 
 
Figure 3. Superposition of UV spectra of a sample of LGT (A) and 
placebo (B) in the 400 to 200 nm range.  
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Figure 4. Superposition of chromatograms of solutions containing 
LGT sample and placebo. In minor graphics: LGT peak purity 
evaluation and UV spectra by DAD. 
 
Three independent standard curves with six concentrations 
(range of 0.5 – 20 μg.mL-1) were built to evaluate method 
linearity. The linear regression by the least squares method 
and the analysis of variance (ANOVA) were applied to the 
data. The linearity was proved to two analytical techniques 
used. In quantification using UV method, the correlation 
coefficient (r) was equal to 1.0000 and the determination 
coefficient (R²) equal to 0.9996. In HPLC method, the 
correlation coefficient (r) was equal to 1.0000 and the 
determination coefficient (R²) equal to 0.9999. The analysis 
of variance for linearity of both methods provided a 
significant result for linear regression (p<0.05) without 
deviation from linearity (p>0.05). Intercepts was always no 
statistically significant (p>0.05).  
Method accuracy and precision were evaluated by adding 
the homogenate of crushed tablets to the vessels, in three 
levels, whose LGT content had been previously determined 
as 98.76%. The recovery results are expressed in Table 2, as 
well as the precision evaluated by the intraday and interday 
relative standard deviation (RSD) of each level. All values 
of RSD were below 1% and the recovery results between 
98.81 and 100.96% demonstrate the accuracy of the 
analytical methods. Additionally, the two-tailed Student’s t-
test was performed with 95% confidence for the 
spectrophotometric and chromatographic methods used and 
no significant statistical difference between them was 
obtained (p=0.068).  
 
Table 2. Accuracy and precision results for LGT dissolved in the two days evaluated by HPLC and UV. 
LGT level Day 
Method Accuracy (Recovery, %) Precision (RSD, %) 
 Intraday (n=3) Interday (n=6) Intraday (n=3) Interday (n=6) 
4 mg (80%) 
1 
HPLC 
100.22 
100.58 
0.32 
0.88 
2 100.94 0.60 
1 
UV 
98.81 
99.52 
0.18 
0.89 
2 100.22 0.67 
5 mg (100%) 
1 
HPLC 
100.58 
100.77 
0.90 
0.68 
2 100.96 0.14 
1 
UV 
99.76 
100.01 
0.85 
0.69 
2 100.25 0.54 
6 mg (120%) 
1 
HPLC 
100.05 
100.22 
0.74 
0.44 
2 100.39 0.88 
1 
UV 
100.42 
100.66 
0.36 
0.44 
2 100.89 0.43 
 
No differences were observed in the dissolution profiles for 
the presence of bubbles in the medium and the degassed one 
whose data (not shown) were obtained using both UV 
spectrophotometry and HPLC methods. 
According to FDA (2000), it is not necessary to calculate the 
similarity factor (f2) for the different media when the 
dissolution is greater than or equal to 85% before the 15 
minutes of the dissolution test. Besides, the relative standard 
deviation must be up to 20% in the first points (up to 10 
min) and no greater than 10% in the other points evaluated.  
Figure 5 shows the mean of the different dissolution media 
evaluated, with their respective error bars (n = 4), employing 
also paddle apparatus at 100 rpm. The pH values of the 
different media were measured at the beginning and at the 
end of the test, and there was a small alteration only in HCl 
medium, with pH varying from 1.2 to 1.6. 
 
 
 
 
 
 
 
 
 
Figure 5. LTG dissolution profiles obtained in the media 0.1 M 
HCl, pH 4.5 acetate buffer and pH 6.8 phosphate buffer (n=4) with 
paddle apparatus (100 rpm) and 900 mL volume . 
 
The high solubility of members of the gliptin class was 
pointed out in another dissolution studies. Lange and 
collaborators developed IVIVC for sitagliptin using the pH 
6.8 phosphate medium in the dissolution analysis, velocity 
50 rpm and apparatus 2. For vildagliptin, Barden and 
collaborators carried out a dissolution method in 0.01 M 
HCl medium using apparatus 2 at 50 rpm.12,13 
The dissolution profiles found for the different media 
presented RSDs lower than 20% at the initial points and 
lower than 10% at the other points, and were within the 
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range advocated by the FDA.6 Moreover, there was a 
dissolution of more than 85% of LGT from the tablets up to 
15 minutes of analysis. Thus, the drug attained rapid 
dissolution requirements of the official guidelines to be a 
candidate for biowaiver.  
These biowaiver candidates are part of the list of essential 
medications helping to obtain the approval of generic 
products, especially in developing countries. The LGT is not 
included in this list but is part of a class of drugs for type 2 
Diabetes Mellitus, a metabolic disease considered a 
pandemic, affecting over 347 million people worldwide.14  
 
Conclusions 
 
According to results obtained, UV analytical method was 
considered validated for LGT dissolution analysis, 
respecting all parameters of official validation 
guidelines.15,16 The selected dissolution conditions can be 
used in the quality control routine analysis for LGT tablets. 
Methods using UV and HPLC proved to be interchangeable 
for this purpose. To be a highly aqueous soluble drug, as 
other members of the gliptin class, possibly belonging to 
BCS Class III, with over 85% dissolution in 15 minutes of 
analysis in three different media, the LGT could be fit as a 
biowaiver candidate in accordance with the official 
guidelines.3,6 
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